STOCK MARKET BSE NSE

Alembic Pharmaceuticals gets USFDA nod for anti-depressant drug

Alembic Pharma said Desipramine Hydrochloride Tablets have an estimated market size of USD 7 million for twelve months ending March 2021.

Published: 08th July 2021 12:50 PM  |   Last Updated: 08th July 2021 12:50 PM   |  A+A-

pills, tablets, medicines

For representational purposes.

By PTI

NEW DELHI: Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Desipramine Hydrochloride tablets used in the treatment of depression.

The approved product is therapeutically equivalent to the reference listed drug product Norpramin tablets of Validus Pharmaceuticals LLC.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipramine Hydrochloride tablets USP in the strength of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, Alembic Pharmaceuticals said in a regulatory filing.

Desipramine Hydrochloride Tablets are indicated for the treatment of depression.

Quoting IQVIA data, Alembic Pharma said Desipramine Hydrochloride Tablets have an estimated market size of USD 7 million for twelve months ending March 2021.

Alembic has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from the USFDA.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp